Teva Pharmaceuticals USA Recall: Glipizide Extended-Release Tablets (anti-diabetic agent),
Teva Pharmaceuticals USA Recall: Glipizide Extended-Release Tablets (anti-diabetic agent), is one of 9,000 recalls in the RecallGuard dataset. Key details — Recalling firm: Teva Pharmaceuticals USA; Product: Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton
| Recalling firm | Teva Pharmaceuticals USA |
|---|---|
| Product | Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15 |
| Reason for recall | Failed Moisture Limits: out of specification test results for water content obtained during stability testing. |
| Classification | Class III (least serious — unlikely to cause adverse health consequences) |
| Status | Terminated |
| Distribution | Product distributed to OH, IL, PA, MI, VA and CT |
| Recall initiated | 20170802 |
| Recall number | D-1058-2017 |
| Category | drug |
| State | PA |
| Country | United States |
$29/mo
Try RecallGuard →